Iltefat Hamzavi, MD

Panelists discuss how the role of AI in Hidradenitis Suppurativa and the potential for complex multi-input factors.

Panelists discuss how artificial intelligence could revolutionize HS diagnosis through automated image analysis, pattern recognition of clinical presentations, and improved early detection capabilities, potentially reducing diagnostic delays.

Panelists discuss future innovations in hidradenitis suppurativa (HS) treatment and recommendations for guidelines and support groups.

Panelists discuss how current HS treatments, ranging from topical antibiotics to biologics, show varying degrees of efficacy in managing symptoms, while highlighting the need for individualized treatment approaches based on disease severity and patient factors.

Panelists discuss how hidradenitis suppurativa significantly impacts patients' quality of life through chronic pain, skin lesions, and social stigma, while remaining frequently misdiagnosed or diagnosed late due to low disease awareness among healthcare providers.

Iltefat Hamzavi, MD, discusses the REGINA 007 phase 2 trial evaluating MK-6194 for the treatment of non-segmental vitiligo.

Iltefat Hamzavi, MD, reviews late-breaking data at AAD on upadacitinib as monotherapy.

Hamzavi spoke at the 2023 Pigmentary Disorder Exchange Symposium in Chicago.